Catalyst Pharmaceuticals, Inc.
Symbol: CPRX
NASDAQ
14.72
USDMarktpreis heute
21.9975
P/E-Verhältnis
-0.6049
PEG-Verhältnis
1.73B
MRK Kapital
- 0.00%
DIV Rendite
Catalyst Pharmaceuticals, Inc. (CPRX) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 585.64 | 137.6 | 298.4 | 191.3 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 19.8 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 177.76 | 53.5 | 10.4 | 6.6 | |||||||||||||||||||||
balance-sheet.row.inventory | 45.76 | 15.6 | 6.8 | 7.9 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 20.18 | 12.5 | 5.2 | 4.4 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 851.23 | 219.3 | 320.8 | 210.1 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.3 | 3.7 | 3.6 | 4 | |||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 720.84 | 194 | 32.5 | 0 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 720.84 | 194 | 32.5 | 0 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 396.9 | 16.5 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 119.5 | 38.3 | 18.7 | 23.7 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | -367.51 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 885.02 | 252.6 | 54.8 | 27.7 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 1736.24 | 471.9 | 375.6 | 237.8 | |||||||||||||||||||||
balance-sheet.row.account-payables | 27.2 | 14.8 | 4 | 2.8 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 1.43 | 0.4 | 0.3 | 0.3 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 24.14 | 0.7 | 8.7 | 0.1 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 13.31 | 3.2 | 3.6 | 3.9 | |||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | -1.3 | 0 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.79 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 113.97 | 60.2 | 53.3 | 0.2 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 47.78 | 8 | 17.6 | 3.9 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 14.03 | 3.2 | 3.6 | 3.9 | |||||||||||||||||||||
balance-sheet.row.total-liab | 290.86 | 84 | 75.2 | 31 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 0.43 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | 404.32 | 121.3 | 49.9 | -26.3 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.06 | 0 | 0 | -0.1 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1040.58 | 266.5 | 250.4 | 233.2 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 1445.38 | 387.9 | 300.4 | 206.8 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1736.24 | 471.9 | 375.6 | 237.8 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-equity | 1445.38 | 387.9 | 300.4 | 206.8 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1736.24 | - | - | - | |||||||||||||||||||||
Total Investments | 396.9 | 16.5 | 0 | 19.8 | |||||||||||||||||||||
balance-sheet.row.total-debt | 14.4 | 3.6 | 3.9 | 3.9 | |||||||||||||||||||||
balance-sheet.row.net-debt | -571.24 | -134.1 | -294.5 | -167.6 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 71.41 | 71.4 | 83.1 | 39.5 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 32.88 | 33.1 | 1.2 | 0.2 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.82 | -17.8 | 4.9 | 9.3 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 14.25 | 14.3 | 7.9 | 6.1 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -37.32 | -37.3 | 13.7 | 5 | ||||||||||||||||||||
cash-flows.row.account-receivables | -43.08 | -43.1 | -3.8 | -0.6 | ||||||||||||||||||||
cash-flows.row.inventory | -4.74 | -4.7 | 1.1 | -3.2 | ||||||||||||||||||||
cash-flows.row.account-payables | 10.82 | 10.8 | 1.2 | -1.5 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 25.34 | -0.3 | 15.3 | 10.4 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 80.2 | 79.9 | 5.2 | 0.3 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 143.6 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -115.52 | -198.5 | 0 | -1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 10 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -13.46 | -13.5 | -10 | -10 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 19.2 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -243.81 | -81.5 | -10 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -293.5 | -293.5 | 9.2 | -11 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 2.79 | 2.8 | 4.1 | 4.1 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -6.9 | -12.1 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | -13.65 | -13.6 | 4.5 | -0.2 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -10.86 | -10.9 | 1.7 | -8.1 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -160.76 | -160.8 | 127 | 41.2 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 585.64 | 137.6 | 298.4 | 171.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 746.4 | 298.4 | 171.4 | 130.2 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 143.6 | 143.6 | 116 | 60.4 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -115.52 | -198.5 | 0 | -1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 28.08 | -54.9 | 116 | 59.4 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 398.2 | 398.2 | 214.2 | 140.8 | ||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 61.03 | 84.5 | 34.4 | 21.9 | ||||||||||||||||||||||
income-statement-row.row.gross-profit | 337.18 | 313.7 | 179.8 | 118.9 | ||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
income-statement-row.row.research-development | 93.15 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 47.02 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 86.69 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-expenses | 12.53 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.operating-expenses | 250.37 | 226.9 | 78 | 66.6 | ||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 311.39 | 311.4 | 112.4 | 88.4 | ||||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 3.6 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -4.1 | 0 | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 86.69 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 7.7 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 12.53 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 7.7 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -4.1 | 0 | ||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.81 | 33.1 | 1.2 | 0.2 | ||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 119.62 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.operating-income | 86.81 | 86.8 | 101.8 | 52.4 | ||||||||||||||||||||||
income-statement-row.row.income-before-tax | 94.51 | 94.5 | 104.7 | 52.7 | ||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 23.1 | 23.1 | 21.6 | 13.2 | ||||||||||||||||||||||
income-statement-row.row.net-income | 71.41 | 71.4 | 83.1 | 39.5 |
Häufig gestellte Frage
Wie hoch ist die Catalyst Pharmaceuticals, Inc. (CPRX) Gesamtvermögen?
Catalyst Pharmaceuticals, Inc. (CPRX) Gesamtvermögen ist 471907000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 213256000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.847.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.263.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.179.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.218.
Was ist der Catalyst Pharmaceuticals, Inc. (CPRX) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 71410000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 3557000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 226860000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 137636000.000.